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1  | INTRODUC TION
Asthma is a highly prevalent respiratory condition affecting 358 mil‐
lion people globally,1 characterized by respiratory symptoms (wheeze, 
shortness of breath, chest tightness and/or cough) and variable ex‐
piratory airflow limitation.2 Asthma is usually associated with airway 
inflammation and airway hyper‐responsiveness, resulting in bronchoc‐
onstriction upon exposure to specific allergens or nonspecific irritants. 
Before treatment, most patients with asthma present with chronic in‐
flammation affecting all airways, including the upper respiratory tract 
and nose, with the medium‐sized bronchi being most affected.3
The structural changes (airway remodelling) that take place in 
the airways of people with asthma include many deleterious pro‐
cesses, for example epithelial damage, goblet cell hyperplasia with 
mucus hypersecretion, thickening of the basement membrane due 
to subepithelial fibrosis, increased airway smooth muscle (ASM) 
mass and increased vascularization in airway walls.3
Two broad key asthma endotypes have been identified, catego‐
rized by the degree of T helper type 2 (Th2) cell inflammation pres‐
ent; these are known as “T2‐high” and “T2‐low” asthma.4 “T2‐high” 
asthma is eosinophilic, while “T2‐low” asthma consists of a subgroup 
of patients whose asthma is persistently noneosinophilic, either pre‐
dominantly neutrophilic or paucigranulocytic.5‐7
While asthma is known to the general public as an allergic dis‐
ease, this may only be true in up to half of cases in adulthood, with 
the remainder being of nonallergic origin. This underscores the im‐
portance of both the allergen and non‐allergen‐dependent path‐
ways in its pathogenesis.8,9 Furthermore, it is now becoming clear 
that both arms (allergen‐dependent and non‐allergen‐dependent) 
are involved in ‘T2‐high’ (eosinophilic) asthma.8 The non‐allergen‐
dependent (innate) pathway is activated by infectious, chemical or 
physical stimuli acting on the epithelium,8 releasing the cytokines 
interleukin (IL)‐25, IL‐33 and thymic stromal lymphopoietin (TSLP) 
which in turn activate type‐2 innate lymphoid cells (ILC2).10 The 
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Abstract
Current research suggests that the prostaglandin D2 (PGD2) receptor 2 (DP2) is a 
principal regulator in the pathophysiology of asthma, because it stimulates and ampli‐
fies the inflammatory response in this condition. The DP2 receptor can be activated 
by both allergic and nonallergic stimuli, leading to several pro‐inflammatory events, 
including eosinophil activation and migration, release of the type 2 cytokines inter‐
leukin (IL)‐4, IL‐5 and IL‐13 from T helper 2 (Th2) cells and innate lymphoid cells type 
2 (ILCs), and increased airway smooth muscle mass via recruitment of mesenchy‐
mal progenitors to the airway smooth muscle bundle. Activation of the DP2 recep‐
tor pathway has potential downstream effects on asthma pathophysiology, including 
on airway epithelial cells, mucus hypersecretion, and airway remodelling, and con‐
sequently might impact asthma symptoms and exacerbations. Given the broad dis‐
tribution of DP2 receptors on immune and structural cells involved in asthma, this 
receptor is being explored as a novel therapeutic target.
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allergen‐dependent pathway is induced after sensitization by aller‐
gens, resulting in stimulation of antigen‐presenting dendritic cells 
and activation of CD4+ Th2 cells.11 Interestingly, TSLP plays a role in 
allergic sensitization and thus is involved in both allergic‐ and non‐al‐
lergic‐mediated T2‐high asthma.
Evidence is accumulating for a key role for the prostaglandin D2 
(PGD2) receptor 2 (DP2) pathway in the pathophysiology of asthma. 
The DP2 receptor, one of three PGD2 receptors, PGD2 receptor 1, 
DP2 and the thromboxane receptor (TP), is a G‐protein‐coupled 
receptor (GPCR), previously identified as ‘chemoattractant recep‐
tor‐homologous molecule expressed on Th2 cells’ (CRTh2).12‐14 
However, the DP2 receptor is not only expressed on Th2 cells, but 
also on many other hematopoietic and structural cells with key roles 
in asthma pathogenesis, including ILC2, eosinophils, basophils, mast 
cells, epithelial cells and airway smooth muscle cells. This has led to 
significant interest in the therapeutic potential of blockage of the 
DP2 receptor pathway.
15‐22 Here we review the impact of DP2 re‐
ceptor pathway activation, and the resulting downstream effects on 
asthma pathogenesis.22,23
2  | PROSTAGL ANDINS
Prostaglandins modulate several physiological systems, as well as 
being involved in a wide range of disease states. They are synthe‐
sized sequentially from arachidonic acid by cyclooxygenase‐1 and 
cyclooxygenase‐2 and prostaglandin synthase enzymes.24 PGD2 is 
synthesized by prostaglandin D synthase enzymes (PGDS).25 Altered 
levels of hematopoietic PGDS (H‐PGDS) may have a role in the 
pathophysiology of asthma.26
PGD2 mediates a number of physiological effects in a range of 
tissues and organs, including inhibition of platelet aggregation,27 
and sleep induction.24 PGD2 is a powerful bronchoconstrictor, in 
people with and without asthma 28,29 and induces vasodilation.30 
Conversely, PGD2 can have muscle relaxant and vasoconstrictive 
properties in other tissues.27 In the airways, PGD2 also induces 
mucus secretion,31 as well as being an inflammatory mediator.24
3  | DP 2 RECEPTOR PATHWAY AC TIVATION
DP1, DP2 and TP receptors mediate the biological effects of PGD2 
(Table 1). All three are rhodopsin‐like seven‐transmembrane‐span‐
ning GPCRs. The DP1 receptor mediates vasodilatory effects of 
PGD2
32 and has both inflammatory and anti‐inflammatory proper‐
ties.24 The TP receptor mediates platelet aggregation and vascu‐
lar and airway smooth muscle constriction.24,33The DP2 receptor 
is structurally distinct from DP1 and TP. The DP2 receptor is a 
chemokine receptor, belonging to the chemoattractant receptor 
branch of the GPCRs.34 As well as PGD2, several PGD2‐derived 
metabolites also bind to and activate the DP2 receptor, includ‐
ing 13,14‐dihydro‐15‐keto‐PGD2, Δ
12PGD2, Δ
12PGJ2, 15‐deoxy‐
Δ12,14PGD2, 15‐deoxy
12,14PGJ2 and 9α11βPGF2, suggesting a T
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broader and more diverse range of ligands for the DP2 receptor 
compared with DP1.
33
The DP2 receptor shows broad cellular and tissue expres‐
sion.33 With regard to inflammatory cells, DP2 receptors are 
expressed on the cell surface of CD8+ T2 cells, Th2 cells,35 eo‐
sinophils and basophils,36 ILC2s37 and monocytes.38 Meanwhile, 
human mast cells express DP2 receptors intracellularly.
39 The DP2 
receptor is also expressed on structural cells including airway ep‐
ithelial cells, along with inflammatory cells within the epithelial 
submucosa, including CD3+ T cells and eosinophils.40 Patients 
with asthma have an increased number of T cells expressing the 
DP2 receptor within the submucosal compartment compared with 
those without asthma; accumulation of these T cells is closely as‐
sociated with severity of asthma.40 This may be a result of the 
known effect of the DP2 receptor pathway on apoptosis of Th2 
cells.41 Additionally, ASM cells from patients with asthma express 
the DP2 receptor.
42
PGD2 binds to the DP2 receptor as part of both the allergen‐de‐
pendent (acquired) and non‐allergen‐dependent (innate) immune 
response (Figure 1). In subjects with asthma, PGD2 is released pri‐
marily from mast cells,43 but is also released in lower concentrations 
from Th2 cells44 and antigen‐presenting dendritic cells,45 following 
stimulation of either the allergen‐dependent or the non‐allergen‐de‐
pendent pathways, or both pathways.46 Binding of the DP2 receptor 
by PGD2 on Th2 cells leads to the release of type 2 cytokines, no‐
tably IL‐4, IL‐5 and IL‐13.47 The DP2 receptor also mediates the ILC2 
response to PGD2, resulting in the migration of these cells to sites of 
inflammation and release of the same cytokines (IL‐5, and IL‐13 and 
to a lesser extent, IL‐4).48 Release of IL‐13 from ILC2s in response 
to DP2 receptor activation is upregulated in the presence of IL‐25 
F I G U R E  1   The DP2 receptor pathway and its downstream effects (not to scale). The non‐allergen‐dependent (innate immunity) pathway 
is activated by infectious, chemical or physical stimuli causing the epithelium to release the cytokines interleukin (IL)‐25, IL‐33 and thymic 
stromal lymphopoietin (TSLP).10 In allergic (i.e. allergen‐sensitized) subjects, exposure to allergens induces the allergen‐dependent (adaptive 
immunity) pathway, stimulating antigen‐presenting dendritic cells and activating T helper 2 (Th2) cells.11 Prostaglandin D2 (PGD2) is released 
from antigen‐presenting cells, mast cells and to a lesser extent from Th2 cells.44‐46 Binding of PGD2 causing DP2 receptor activation on Th2 
cells and ILC2s releases cytokines with further downstream effects on airway epithelial cells. DP2 receptor activation also leads to ILC2 
migration and to amplification of type 2 cytokine production induced by IL‐25 or IL‐33 from ILC2s, 48 while binding to airway smooth muscle 
cells affects cell proliferation and migration, contributing to the increased amount of airway smooth muscle.42,47,48 Furthermore, binding of 
the DP2 receptor by PGD2 activates eosinophils indirectly through two pathways: one mediated by IL‐5 and a second via eotaxins, mediated 
by IL‐4 and IL‐13.58,59 Direct eosinophil activation by PGD2 via DP2 induces migration of eosinophils, eosinophil shape change, chemokinesis 
and degranulation.12,13 IL: interleukin; TSLP: thymic stromal lymphopoietin; Th2; T helper 2 cells; PGD2: prostaglandin D2; ILC2: innate 
lymphoid cells type 2; DP2: prostaglandin D2 receptor 2
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and IL‐33 released from the airway epithelium.49 In addition, DP2 
receptor activation in combination with either IL‐25 or IL‐33 has a 
synergistic effect on cytokine production from ILC2s (Figure 1).48 
Recent research shows that autocrine control, within ILC2s, may be 
a mechanism by which DP2 receptor activation has a local immuno‐
modulatory role beyond the major PGD2 release from mast cells.
50
Subsequent to their release, IL‐4, IL‐5 and IL‐13 have numer‐
ous effects on the cells and tissues of the inflammatory pathways 
in asthma. Meanwhile, these inflammatory cytokines are involved 
in several other inflammatory conditions beyond asthma. IL‐4 and 
IL‐13 have an important role in the pathogenesis of chronic sinusitis 
with nasal polyps and atopic dermatitis.51 IL‐5 is implicated in allergic 
rhinitis,52 atopic dermatitis,53 idiopathic pulmonary fibrosis, Churg‐
Strauss syndrome (eosinophilic granulomatosis and polyangiitis),54 
eosinophilic oesophagitis55 and hypereosinophilic syndrome.56
Eosinophils are important inflammatory effector cells in type 2 
asthma. They are mainly synthesized in the bone marrow from eosin‐
ophil progenitor cells, in response to allergic stimuli in the airways.57 
These induced eosinophils (iEos)8 are released into the blood stream 
from the bone marrow, mediated mostly by IL‐5.57 Eosinophils are 
activated by binding of the DP2 receptor by PGD2, 
58 through two 
pathways: one mediated by IL‐5, and a second via eotaxins driven by 
IL‐4 and IL‐1359 (Figure 1). Eosinophil activation induces migration of 
eosinophils,13 shape change, chemokinesis and degranulation.12 The 
migration of eosinophils from the blood stream to the bronchial mu‐
cosa is mediated by endothelial adhesion molecules such as vascular 
cell adhesion molecule‐1 (VCAM‐1) and P selectin, whose expression is 
facilitated by IL‐4 interacting with tumour necrosis factor (TNF)‐α.60,61
Initial study in mice indicates that a second group of eosino‐
phils, known as resident eosinophils (rEos), may be present in the 
lung parenchyma,57 potentially part of a wider group of homeostatic 
eosinophils resident in other tissues.62 These findings need to be 
confirmed by further research, including in humans.
4  | THE IMPORTANCE OF THE DP 2 
RECEPTOR PATHWAY
The DP2 receptor pathway amplifies the inflammatory reaction, by 
enhancing and increasing the immune response. This amplification 
is illustrated in studies of PGD2 and other inflammatory mediators, 
including a second group of arachidonic acid derivatives, cysteinyl 
leukotrienes (cysLTs), in Th2 cells and ILC2s.48,63,64
In Th2 cells, cysLTs acting alone are weak inducers of the type 2 
cytokine IL‐13, compared with induction via the DP2 receptor path‐
way with PGD2. However, the cysLT leukotriene E4 (LTE4) acting to‐
gether with PGD2 results in an amplified response in induction of all 
three cytokines, IL‐4, IL‐5 and IL‐13.64
Stimulation of the DP2 receptor pathway with PGD2 has a 4.5 
times greater effect than IL‐33 on ILC2 migration, although there 
is no additive effect of these mediators in combination.48 Similarly, 
in terms of cytokine production, PGD2 induces the production of 
IL‐4, IL‐5 and IL‐13 from ILC2 more strongly than IL‐25 and IL‐33. 
Importantly, PGD2 has a synergistic effect on type 2 cytokine pro‐
duction induced by IL‐25 or IL‐33 (Figure 1).
The combination of PGD2 and LTE4 has an additive effect on ILC2 
migration, in contrast to when LTE4 is combined with either of the 
cytokines IL‐25, IL‐33 or TSLP, where no additive effect is seen.63 
Furthermore, PGD2 and LTE4 in combination have a synergistic ef‐
fect on the production of some ILC2‐derived cytokines (IL‐4, IL‐8, 
granulocyte‐macrophage colony‐stimulating factor, macrophage‐
stimulating factor and amphiregulin) and an additive effect on other 
type 2 cytokines (IL‐5 and IL‐13). The accumulation of evidence from 
these in vitro studies suggests a central role for the DP2 receptor 
pathway, not only in the stimulation of the inflammatory response, 
but also in the amplification of the response to other inflammatory 
mediators, including cysLTs, IL‐25 and IL‐33.
5  | DOWNSTRE AM EFFEC TS OF DP 2 
RECEPTOR AC TIVATION AND CLINIC AL 
CONSEQUENCES
The central role of DP2 receptor activation in the inflammatory cas‐
cade leads to numerous downstream effects on cells and tissues 
involved in the pathophysiology of asthma with biological conse‐
quences, including effects on airway epithelial cells, airway remod‐
elling through subepithelial fibrosis, effects on ASM and mucus 
hypersecretion (Figure 1). The pivotal role of DP2 receptor pathway 
activation suggests a role in asthma exacerbations.65‐67
5.1 | Airway epithelial cells
Airway epithelial cells express multiple inflammatory proteins and 
release cytokines, chemokines and lipid mediators in response 
to various stimuli.3 Biopsy specimens show that people with 
asthma have reduced numbers of DP2 receptor‐positive epithe‐
lial cells compared with those without asthma and that this re‐
duction is associated with the severity of asthma.40 A potential 
effect of stimulation of the DP2 receptor pathway on the airway 
epithelium is through the recruitment and activation of eosino‐
phils, which causes damage to the airway mucosa and associated 
nerves through release of granule‐associated basic proteins, and 
also through the release of reactive oxygen species, which cause 
injury to mucosal cells.68
Mucus hypersecretion in asthma occurs as a result of increased 
numbers of goblet cells in the airway epithelium and increased size 
of the submucosal glands,3 which are mediated by elements of the 
DP2 receptor pathway. Mucus production is stimulated by IL‐13 (and/
or IL‐4) secreted from Th2 cells and ILC2, either by acting directly 
on mucus‐secreting goblet cells or indirectly through mediators ac‐
tivated in the lung.69 Furthermore, IL‐13 released from Th2 and ILC2 
induces goblet cell hyperplasia.70 In a mouse model of chronic airway 
inflammation, a DP2 receptor antagonist caused a reduction in goblet 
cell hyperplasia and mucus production, as well as inhibiting airway 
eosinophilia.71
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5.2 | Airway remodelling
Airway remodelling in asthma results in persistent airflow limitation, 
a decrease in lung function, and airway hyper‐responsiveness.72 The 
structural changes involved in airway remodelling include subepi‐
thelial fibrosis (increased collagen content of the subepithelial tissue 
just beneath the basement membrane), increased ASM mass and in‐
creased blood vessels in airway walls.3
Fibrosis in the airway tissue may be a downstream effect of 
eosinophil proliferation. Specifically, transforming growth factor 
(TGF)‐β derived from activated eosinophils might be involved in fi‐
brosis of the airways of people with asthma.73 Further evidence for 
the role of eosinophils in airway remodelling comes from a study in 
which treatment with an anti‐IL‐5 antibody decreased the number of 
eosinophils in the airways and reduced airway remodelling in mild‐
to‐moderate asthma, represented by reduced deposition of eosino‐
phil‐derived extracellular matrix proteins and decreased numbers of 
myofibroblasts.68,74 However, the clinical implications of this are yet 
to be confirmed.
Airway smooth muscle in people with asthma shows both pro‐
liferation (hyperplasia) and growth (hypertrophy).3 Infiltration of the 
ASM by mast cells releasing PGD2 has subsequent effects on the 
inflammatory cascade through binding of the DP2 receptor on eo‐
sinophils and ASM cells. In a mouse model of chronic asthma, eo‐
sinophil‐deficient mice had significantly less ASM hyperplasia than 
wild‐type mice, which was associated with decreased TGF‐β‐posi‐
tive cells, mostly eosinophils.55
In addition to the effect of PGD2 on eosinophils, DP2 receptor 
activation on the surface of ASM cells is likely to be involved in the 
promotion of ASM cell migration and to contribute to increased 
ASM mass in asthma.42 Moreover, DP2 receptor antagonism reduces 
ASM cell migration and filamentous actin (microfilament) content 
in ASM cells.42 This may also be linked to airway hyper‐responsive‐
ness, which involves excessive contraction of ASM cells, uncoupling 
of airway contraction, thickening of the airway wall and effects on 
sensory nerves.3
In summary, the clinical implications of DP2 receptor pathway ac‐
tivation are likely to be related to the resulting downstream effects on 
the airways. These include effects on inflammatory cells and direct 
effects of DP2 receptor activation on structural cells such as epithelial 
cells and ASM cells. Eosinophil degranulation causes damage to the 
airway mucosa and nerves, and affects airway remodelling through 
effects on fibrosis, as well as influencing ASM cell hyperplasia. ASM 
cells are also affected directly by DP2 receptor activation, resulting 
in cell migration and increased ASM mass. Mucus hypersecretion is 
induced by DP2 receptor pathway activation through IL‐4 and IL‐13 
released from Th2 and ILC2, as well as the induction of goblet cell 
hyperplasia through IL‐13.
DP2 receptor pathway activation may also influence asthma 
exacerbations. Severe exacerbations are associated with upper re‐
spiratory tract viral infections and exposure to allergens,66 or both 
synergistically.65 Activation of the DP2 receptor pathway is involved 
in both the allergen‐dependent and non‐allergen‐dependent immune 
pathways, suggesting that activation of this pathway is likely to have 
an effect on asthma exacerbations. For example, the DP2 receptor 
pathway is induced by viral RNA resulting in an increase in eosino‐
phil accumulation; therefore, the allergic response may be amplified 
through the presence of viral RNA.67
6  | EFFEC TS OF DP 2 RECEPTOR 
BLOCK AGE ON A STHMA
Limitations of the current treatment options for asthma have led 
to the investigation of the potential of DP2 receptor antagonism 
as a therapeutic option. Given the multiple downstream effects 
discussed above, the DP2 receptor pathway appears to be a de‐
sirable target for investigation. There are currently several drugs 
in development targeting this pathway with varying degrees of 
success.22,23
A study of 79 patients with inadequately controlled asthma with 
the dual antagonist of human D‐prostanoid and DP2 receptors, AMG 
853, showed no effect on asthma control or on any of the secondary 
endpoints.75
The DP2 receptor antagonist OC000459 was investigated in a 
study of 132 steroid‐free patients with moderate persistent asthma. 
This study met its primary endpoint of a significant difference in 
FEV1 for the per protocol population, but not for the full analysis 
population. Quality of life and night‐time symptoms improved sig‐
nificantly for both populations, but not sputum eosinophil counts.76 
In	a	second	study	of	16	patients,	OC000459	showed	significant	re‐
duction in the late asthma response, but not the early asthma re‐
sponse compared with placebo. A significant reduction in sputum 
eosinophil counts and difference in eosinophil shape change was 
also seen compared with placebo.77
Fevipiprant, the most advanced of the DP2 receptor antagonists 
in development, is an orally delivered, highly selective, reversible 
DP2 receptor antagonist.
78 Pharmacological studies have shown 
that fevipiprant is a competitive inhibitor of DP2 receptor‐mediated 
responses involved in asthma.79 Furthermore, fevipiprant has a short 
time to peak plasma concentration, has a long half‐life, does not in‐
teract with food and is excreted through multiple pathways reducing 
the risk of drug‐drug interactions and pharmacogenetic or ethnic 
variability.78,80
In Phase II clinical trials, fevipiprant had a positive effect on lung 
function in patients with asthma, as well as improving control and 
quality of life.15,16,18	In	a	study	of	61	patients	with	persistent	eosino‐
philic asthma, those treated with fevipiprant had a 3.5 times greater 
reduction in eosinophilic airway inflammation (the primary outcome) 
than those treated with placebo.18 There is preliminary evidence to 
suggest that fevipiprant has a healing effect on the airway epithe‐
lium,18 as well as reducing ASM mass in people with asthma.42 All 
studies to date show a favourable safety and tolerability profile for 
fevipiprant.
A worldwide Phase III programme of fevipiprant is currently 
under way which may help to further our understanding of the 
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benefits of DP2 receptor antagonism on clinical outcomes in patients 
with asthma.
The effects of these drugs on the DP2 receptor pathway may not 
be limited to asthma. DP2 receptor expression is seen in mast cells and 
fibroblasts in nasal polyp tissue, on T cells in the nasal mucosa of pa‐
tients with allergic rhinitis and in Th2 cells in patients with atopic der‐
matitis, indicating that there may also be potential for positive effects 
of DP2 receptor antagonism in other organs and conditions.
39,81,82 
Data also suggest a potential role for antagonism of the DP2 receptor 
pathway in reducing eosinophilic inflammation in patients with COPD, 
but not on clinical outcomes to date.83 Further investigation is required 
to determine potential clinical effect in COPD.
7  | CONCLUSION
Activation of the DP2 receptor pathway through both the allergen‐
dependent and non‐allergen‐dependent pathways elicits multiple 
downstream effects. These are mediated by the release of important 
inflammatory mediators including the type 2 cytokines IL‐4, IL‐5 and 
IL‐13, as well as the activation of eosinophils, one of the key effector 
cells in type 2 asthma that are associated with an increased risk of 
exacerbations. Activation of the DP2 receptor may have direct ef‐
fects on the airway epithelium and on increasing ASM mass. The role 
of DP2 receptor binding by PGD2 as both an inducer and amplifier of 
inflammatory pathways is becoming increasingly clear. Activation of 
the pathway has numerous downstream effects and biological con‐
sequences, including on airway epithelium and smooth muscle, air‐
way remodelling, mucus hypersecretion and possibly exacerbations. 
The broad range of expression of the DP2 receptor on hematopoietic 
and structural cells involved in the pathogenesis of asthma and the 
encouraging initial clinical trials of the DP2 receptor antagonist, fevi‐
piprant, support the view that DP2 receptor antagonism is an attrac‐
tive therapeutic target for asthma.
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